Alnylam Pharamceuticals Announcement
June 24, 2024, Alnylam Pharmaceuticals (ALNY) announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM).

The study met the primaary endpoint. It demonstrated a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular . . .